Daklinza Dosage
Generic name: DACLATASVIR DIHYDROCHLORIDE 90mg
Dosage form: tablet
Drug class: NS5A inhibitors
Medically reviewed by Drugs.com. Last updated on Oct 7, 2024.
Testing Prior to the Initiation of Therapy
Testing for HBV infection: Test all patients for evidence of current or prior HBV infection by measuring hepatitis B surface antigen (HBsAg) and hepatitis B core antibody (anti-HBc) before initiating HCV treatment with DAKLINZA.
NS5A Resistance Testing in HCV Genotype 1a-Infected Patients with Cirrhosis: Consider screening for the presence of NS5A polymorphisms at amino acid positions M28, Q30, L31, and Y93 in patients with cirrhosis who are infected with HCV genotype 1a prior to the initiation of treatment with DAKLINZA and sofosbuvir with or without ribavirin.
Recommended Dosage
The recommended dosage of DAKLINZA is 60 mg, taken orally, once daily, with or without food.
Table 1 provides the recommended DAKLINZA-containing treatment regimens and duration based on HCV genotype and patient population. The optimal duration of DAKLINZA and sofosbuvir with or without ribavirin has not been established for HCV genotype 3 patients with cirrhosis or for HCV genotype 1 patients with Child-Pugh C cirrhosis.
For patients with HCV/HIV-1 coinfection, follow the dosage recommendations in Table 1. Refer to Drug Interactions (7) for dosage recommendations for concomitant HIV-1 antiviral drugs.
For specific dosage recommendations for sofosbuvir, refer to the prescribing information.
For HCV genotype 1 or 3 patients with Child-Pugh B or C cirrhosis or post-transplantation patients, the starting dose of ribavirin is 600 mg once daily, increasing up to 1000 mg daily as tolerated. The starting dose and on-treatment dose of ribavirin can be decreased based on hemoglobin and creatinine clearance.
For HCV genotype 3 patients with compensated cirrhosis (Child-Pugh A), the recommended dosing of ribavirin is based on weight (1000 mg for patients weighing less than 75 kg and 1200 mg for those weighing at least 75 kg administered orally in two divided doses with food).
Patient Population | Treatment and Duration | |
---|---|---|
Genotype 1 |
Without cirrhosis |
DAKLINZA + sofosbuvir for 12 weeks |
Compensated (Child-Pugh A) cirrhosis |
||
Decompensated (Child-Pugh B or C) cirrhosis |
DAKLINZA + sofosbuvir + ribavirin |
|
Post-transplant |
||
Genotype 3 |
Without cirrhosis |
DAKLINZA + sofosbuvir for 12 weeks |
Compensated (Child-Pugh A) or |
DAKLINZA + sofosbuvir + ribavirin |
|
Post-transplant |
Dosage Modification Due to Drug Interactions
Refer to the drug interactions and contraindications sections for other drugs before coadministration with DAKLINZA.
Concomitant Drugs | DAKLINZA Dosage |
---|---|
Strong CYP3A inhibitors and certain HIV antiviral agents |
30 mg once daily |
Moderate CYP3A inducers and nevirapine |
90 mg once daily |
Strong CYP3A inducers |
Contraindicated |
Dosage reduction of DAKLINZA for adverse reactions is not recommended.
Frequently asked questions
More about Daklinza (daclatasvir)
- Check interactions
- Compare alternatives
- Reviews (10)
- Drug images
- Side effects
- During pregnancy
- FDA approval history
- Drug class: NS5A inhibitors
- Breastfeeding
Patient resources
Professional resources
Related treatment guides
Further information
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.